Uveitis

Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

Retrieved on: 
Friday, July 8, 2022
Weight gain, Patient, GLOBE, Retina, Cancer, AIFA, Osteoporosis, Uveitis, Recurrence, Injection, Alimera Sciences, Analysis, SIFI, Organization, Financial condition report, SEC, Result, Associate, Eye, Lists of countries and territories, Inflammation, Lists of diseases, DME, Severe cognitive impairment, Infection, Private Securities Litigation Reform Act, Sleep, Italian Medicines Agency, Hypertension, Mutual, Diabetic retinopathy, News, Acne, Annual report, Vita-Salute San Raffaele University, Disease, Compte rendu, Risk, Fluocinolone acetonide, Intraocular pressure, Physician, European Medicines Agency, Pharmaceutical industry, Trosia

Alimera will launch ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant behind its new uveitis indication in Italy, through its distribution partner, SIFI.

Key Points: 
  • Alimera will launch ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant behind its new uveitis indication in Italy, through its distribution partner, SIFI.
  • The Companys primary product is ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into the back of the eye.
  • In March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
  • Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf.

QHP Capital Acquires Lexitas Pharma Services

Retrieved on: 
Thursday, July 7, 2022
Professional Services, Health, Finance, Pharmaceutical, Optical, Biotechnology, Efficiency, Retinitis pigmentosa, Acquisition, Science, Patient, CEO, Ophthalmology, Lists of people executed in the United States, Growth, Company, Industry, Goal, Diversified Pharmaceutical Services, Partner, CRO, Glaucoma, QHP, Duane syndrome, Clinical trial, Technology, Cataract, Board, Diabetic retinopathy, Vance DeGeneres, Drug development, Uveitis, Fine chemical, Pharmaceutical industry

QHP Capital (QHP), the management company for NovaQuest Private Equity (NQPE), today announced its acquisition of Lexitas Pharma Services (Lexitas or the Company), a full-service ophthalmology contract research organization (CRO) supporting biopharmaceutical and medical device clinical trials.

Key Points: 
  • QHP Capital (QHP), the management company for NovaQuest Private Equity (NQPE), today announced its acquisition of Lexitas Pharma Services (Lexitas or the Company), a full-service ophthalmology contract research organization (CRO) supporting biopharmaceutical and medical device clinical trials.
  • Lexitas is an excellent fit with QHPs philosophy and strategy of providing strategic capital to growing clinical trial services providers in niche, specialized therapeutic areas, said Vern Davenport and Jeff Edwards, Partners at QHP.
  • We look forward to supporting the Lexitas team as they continue to build out their capabilities and provide best-in-class ophthalmic drug development services.
  • QHP Capital, L.P. (the Firm), is the management company for NovaQuest Private Equity (NQPE).

Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

Retrieved on: 
Wednesday, July 6, 2022
Suprachoroidal drug delivery, Canadian Securities Administrators, Patient, SCS, Canker, COVID-19, Hypersensitivity, Bausch & Lomb, Bacteria, Lens (anatomy), Floater, Uveitis, Degenerative disease, Pregnancy, Fetus, FDA, Dose, Triamcinolone, ASRS, Conjunctiva, Cataract, Nursing, Hypothalamic–pituitary hormone, Macular edema, NYSE, Cushing's syndrome, Cornea, Instagram, Twitter, Eye, LinkedIn, Administration, Duane syndrome, HPA, Virus, Chickenpox, News, Chalazion, Chemosis, U.S. Securities and Exchange Commission, History, Photophobia, Meibomian gland, Glaucoma, Fungus, Risk, Vaccinia, Cover My Eyes (Pain and Heaven), Visual acuity, Intraocular pressure, Facebook, Fear, Society, Photopsia, Hyperglycemia, Pharmaceutical industry, Silviculture, Vaccine, Telescopic sight

VAUGHAN, ON, July 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that five presentations highlighting data from the XIPERE® (triamcinolone acetonide injectable suspension) pivotal Phase 3 program will be presented at the American Society of Retina Specialists (ASRS) 40th annual scientific meeting, which will take place in New York from July 13-16, 2022. The presentations will include a new post-hoc analysis of the pivotal Phase 3 trial (PEACHTREE) evaluating outcomes following treatment with XIPERE® in patients with macular edema associated with chronic uveitis.

Key Points: 
  • "At this year's ASRS annual meeting, we look forward to sharing these data with retina specialists on XIPERE, which we launched commercially in March," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.
  • Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Outcomes by anatomic subtypes in PEACHTREE.
  • Efficacy of suprachoroidal triamcinolone acetonide injectable suspension in the treatment of macular edema in patients with chronic uveitis.
  • XIPERE(triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

Retrieved on: 
Wednesday, July 6, 2022
Ankylosing spondylitis, OX40L, CDE, AIM, Patient, III, LinkedIn, Atopic dermatitis, Psoriatic arthritis, Adult, OX40, HCM, GLOBE, COVID-19, Population, Cancer, Ligation, U.S. Securities and Exchange Commission, TNFR, Forward-looking statement, National Medical Products Administration, SAN, Therapy, Center, IND, Psoriasis, NMPA, Affibody molecule, HKEX, Silverberg, Sustainable Stock Exchanges Initiative, Private Securities Litigation Reform Act, Safety, Uveitis, Center for Drug Evaluation and Research, Hope, Drug discovery, Protocol, Pharmaceutical industry, Vaccine

Dosing the first participant is an important milestone for the IMG-007 program, said Dr Jonathan Wang, Chairman and Chief Executive Officer of Inmagene.

Key Points: 
  • Dosing the first participant is an important milestone for the IMG-007 program, said Dr Jonathan Wang, Chairman and Chief Executive Officer of Inmagene.
  • We hope the data will help us demonstrate that IMG-007 is one of the strongest OX40 antagonist drug candidates worldwide.
  • It was originally discovered by HUTCHMED, with Inmagene assuming development responsibility at the candidate stage.
  • Inmagene has formed strategic partnerships with multiple partners, such as HUTCHMED and Affibody AB, to develop highly innovative drug candidates.

Nuvation Bio, Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Tuesday, July 5, 2022
Review, FDA, Patient, Breast cancer, GLOBE, Company, Inflammation, Food, NYSE, Prostate cancer, NUVB, Food and Drug Administration, Uveitis, News, Eye, Pharmaceutical industry

​LOS ANGELES, July 05, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nuvation Bio Inc. (“Nuvation” or “the Company”) (NYSE: NUVB) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Nuvation investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, July 05, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nuvation Bio Inc. (Nuvation or the Company) (NYSE: NUVB) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors.
  • Nuvation investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022
Class Action Lawsuit, Professional Services, Legal, Ethics, FDA, Patient, Breast cancer, Company, Suite, Inflammation, Food, Certification, NYSE, Prostate cancer, NUVB, Food and Drug Administration, Uveitis, News, Eye, Security (finance), Pharmaceutical industry

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (Nuvation or the Company) (NYSE: NUVB ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (Nuvation or the Company) (NYSE: NUVB ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022
Professional Services, Class Action Lawsuit, Ethics, FDA, Patient, Breast cancer, Company, Suite, Inflammation, Food, Certification, NYSE, Prostate cancer, NUVB, Food and Drug Administration, Uveitis, News, Eye, Security (finance), Pharmaceutical industry

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (Nuvation or the Company) (NYSE: NUVB ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (Nuvation or the Company) (NYSE: NUVB ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

Retrieved on: 
Monday, June 27, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Patient, Probability, Breast cancer, Cancer, Company, Inflammation, Form 10-Q, Food, NYSE, Medivation, SEC, Risk, Prostate cancer, Private Securities Litigation Reform Act, NUVB, Food and Drug Administration Amendments Act of 2007, Uveitis, Eye, Drug discovery, Forward-looking statement, Pharmaceutical industry

While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.

Key Points: 
  • While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.
  • Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates.
  • Nuvation Bio's proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.
  • Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Retrieved on: 
Tuesday, June 21, 2022
ACT, Industry, Eye, FDA, NDA, Therapy, COVID-19, Inflammation, Annual report, NMPA, National Medical Products Administration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology, Motherboard, Compliance, Cataract, Plasma protein binding, Company, CDE, Center for Drug Evaluation and Research, Forward-looking statement, Private Securities Litigation Reform Act, Uveitis, THE, NASDAQ, News, SEC, Stock exchange, Patient, Food, Glaucoma, Visual impairment, Diagnosis, HKSE, GLOBE, Pharmaceutical industry

In April 2021, the CDE accepted OcuMensions new drug application (NDA) for YUTIQ that was filed with the real-world data collected at Boao Lecheng Super Hospital.

Key Points: 
  • In April 2021, the CDE accepted OcuMensions new drug application (NDA) for YUTIQ that was filed with the real-world data collected at Boao Lecheng Super Hospital.
  • We are thrilled to announce the new drug approval for YUTIQ in China.
  • Non-infectious uveitis affecting the posterior segment of the eye is a chronic form of uveitis that may cause a variety of complications, including cataracts and glaucoma.
  • YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye, and was approved by the FDA onOctober 12, 2018.

Global Ophthalmics Partnering Analysis Report 2014-2022: Trends, Players and Financials for 550+ Deals - ResearchAndMarkets.com

Retrieved on: 
Monday, June 13, 2022
Health, General Health, Orientation, Directory, Research, Biotechnology, Players, Hyperlink, Ocular hypertension, Diabetic retinopathy, Contract, Chapter Three, Visual impairment, Chapter Five, Chapter Four, Chapter Two, Cataract, Finance, A-Z, Technology, Review, Conjunctivitis, Chapter Six, SEC, Uveitis, Pharmaceutical industry, Music, Sales, Ophthalmic pathology, Glaucoma

The "Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Ophthalmics Partnering 2014-2022 report provides comprehensive access to available deals and contract documents for over 550 ophthalmics deals signed between the world's pharmaceutical and biotechnology companies since 2014.
  • In addition, a comprehensive appendix is provided with each report of all Ophthalmics partnering deals signed and announced since 2014.
  • Global Ophthalmics Partnering 2014 to 2022 includes:
    In Global Ophthalmics Partnering 2014 to 2022, available deals and contracts are listed by: